Form 4: NewAmsterdam Pharma Director Louis Lange Converts Restricted Stock Units into Ordinary Shares

NewAmsterdam Pharma Co N.V. Director Louis G. Lange converted 68 Restricted Stock Units into ordinary shares on June 1, 2025, increasing his indirect beneficial ownership to 28,186 shares.

Summary

• Louis G. Lange, a Director of NewAmsterdam Pharma Co N.V. (NAMS), acquired 68 ordinary shares on June 1, 2025.
• This acquisition resulted from the conversion of 68 Restricted Stock Units (RSUs) at a price of $0 per share.
• Following this transaction, Mr. Lange indirectly beneficially owns 28,186 ordinary shares through the LGLange III Trust DTD10.
• The RSUs were granted on March 26, 2025, as earnout RSUs under a business combination agreement dated July 25, 2022, contingent on a clinical development milestone.
• The right to receive these earnout RSUs became fixed and irrevocable on the Closing Date of the business combination.
• Previous RSU vestings included 3,102 upon grant, 69 on April 1, 2025, and 69 on May 1, 2025.

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction (RSU vesting and conversion) as part of a pre-defined compensation plan. While not indicative of new positive news, it reflects the execution of existing agreements and the director's continued ownership, which is generally neutral to slightly positive as it shows alignment of interests.

Positives

• The conversion of RSUs indicates the achievement of vesting conditions, which can be tied to performance or time.
• The RSUs were part of an earnout structure from a business combination agreement, suggesting a milestone was met.

Future Outlook

NA

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically the vesting and conversion of Restricted Stock Units (RSUs) for a director. Such transactions are common in the biotechnology and pharmaceutical industries as part of executive compensation and retention strategies, often tied to performance milestones or time-based vesting schedules. The earnout structure mentioned suggests a pre-defined agreement from a past business combination, which is a common mechanism in M&A to align interests and incentivize post-merger performance.

Related Party Transactions

• The conversion of Restricted Stock Units (RSUs) for Director Louis G. Lange is a related party transaction, as it involves compensation to an insider of the company based on a pre-existing business combination agreement.

Stakeholder Impact

• Shareholders: The transaction increases the director's indirect beneficial ownership, aligning management interests with shareholder value. It also reflects the execution of a pre-defined compensation structure, which is part of the company's overall governance and compensation strategy.

Key Dates

Keywords

NewAmsterdam Pharma, NAMS, Louis G. Lange, Form 4, SEC filing, Insider transaction, Restricted Stock Units, RSU conversion, Ordinary Shares, Director ownership, Beneficial ownership, Earnout, Business Combination Agreement